Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE TrialKJELDSEN, Sverre E; JULIUS, Stevo; ZANCHETTI, Alberto et al.Blood pressure. 2001, Vol 10, Num 2, pp 83-91, issn 0803-7051Article

An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registryVELAZQUEZ, Eric J; FRANCIS, Gary S; VAN GILST, Wiek et al.European heart journal. 2004, Vol 25, Num 21, pp 1911-1919, issn 0195-668X, 9 p.Article

Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of Acute myocardial infarction: The valsartan in Acute myocardial infarction (VALIANT) trialAGUILAR, David; SOLOMON, Scott D; BELENKOV, Yuri N et al.Circulation (New York, N.Y.). 2004, Vol 110, Num 12, pp 1572-1578, issn 0009-7322, 7 p.Article

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothPFEFFER, Marc A; MCMURRAY, John J. V; LEIMBERGER, Jeffrey D et al.The New England journal of medicine. 2003, Vol 349, Num 20, pp 1893-1906, issn 0028-4793, 14 p.Article

Valsartan in Acute Myocardial Infarction Trial (VALIANT) : Rationale and designPFEFFER, Marc A; MCMURRAY, John; SELLERS, Mary Ann et al.The American heart journal. 2000, Vol 140, Num 5, pp 727-734, issn 0002-8703Article